Volpara (ASX:VHT) share price pushes higher on record quarterly update

The company provided investors with its latest performance report.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is climbing today following the release of the company's quarterly report.

At the time of writing, the healthcare technology company's shares are up 1.17% to $1.295.

a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.

Image source: Getty Images

How did Volpara perform for Q2 FY22?

According to its release, Volpara advised record sales and cash inflows for the 3 months ending 30 September.

In particular, cash receipts from customers totalled NZ$7.1 million (A$6.79 million), an increase of 11% on the previous quarter. Compared against the prior corresponding period, this metric grew 52% — or 68% in constant currency terms.

Subscription-based receipts continued to accelerate, representing more than NZ$6.9 million (A$6.60 million) for the 3 months. This is a jump of 63% year-on-year, or roughly 74% in constant currency.

Net operating cash outflow came to NZ$3.8 million (A$3.63 million), consistent with Q2 FY21. Some material supplier contract renewals, such as its annual insurance program, kept the costs in line.

Volpara noted that it closed the quarter with cash of NZ$25 million (AS23.91) on hand and no debt.

On the Software-as-a-Service (SaaS) front, annual recurring revenue (ARR) stood at US$20.4 million (A$27.24) million. Contracts were signed across the company's full product suite as both standalone sales and platform deals. Many existing customers also increased contracts with Volpara whether by adding on products or expanding use of existing products.

The average revenue per user (ARPU) improved to US$1.46 (A$1.95), up 5% on the prior quarter. Its legacy MRS support contracts were heavily weighted towards the lower ARPU ranges, while its subscription-based products weighted more to the higher ARPUs.

Volpara group CEO Dr Ralph Highnam commented:

Q2 is traditionally our weakest quarter for sales, and yet today we've shown that we've had a record quarter not only for sales but also cash inflows.

…Our job now is to keep that momentum and passion for what we do as we go through the second half of the year, keeping in mind potential winter waves of COVID in the northern hemisphere.

Volpara share price summary

The past 12 months have been a disappointing run for investors, with the company's shares down almost 11%. When looking at year-to-date, its losses are hovering around 9% over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $329 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

This ASX healthcare company's profit has rocketed 24%

Expansion into new markets is paying off.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Are these rocketing ASX healthcare shares a must buy?

These companies all rose significantly to start the week.

Read more »

A doctor and an elderly couple sit at a desk and look at a lung scan uploaded.
Healthcare Shares

Why did 4DMedical shares charge higher today, then drop?

The company's key technology has received a big tick.

Read more »

Business woman working from home with stock market chart showing percent change on her laptop screen.
Healthcare Shares

Should I invest $10,000 in CSL shares before the end of May?

This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look.

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

Why this fallen ASX 200 blue chip could be a strong buy

I think the market may be underestimating the durability of this healthcare business.

Read more »

Female pharmacist smiles with a digital tablet.
Broker Notes

3 reasons to buy Sigma Healthcare shares today

A leading analyst expects “impressive growth” from Sigma Healthcare shares.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news.
Healthcare Shares

Could this fallen ASX 200 stock be a once-in-a-decade opportunity?

The valuation now looks far more interesting for a healthcare stock with a global leadership position.

Read more »

Hand dropping a mic.
Healthcare Shares

Pro Medicus shares jump as massive US contract win turns heads

Pro Medicus shares are rocketing after a major US win.

Read more »